Effectiveness of Palonosetron Versus Other Serotonin 5-HT3 Receptor Antagonists in Triple Antiemetic Regimens During Multiday Highly Emetogenic Chemotherapy
Kyung Im Kim(Korea University), Jung Mi Oh(Seoul National University), Hye Suk Lee(Catholic University of Korea), Sung‐Soo Yoon(Seoul National University Hospital), Jeong-Hyun Yoon(Pusan National University), Dong-Eun Lee(Seoul National University), Inhye Cho(Seoul National University)
Cited by 10
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
|Blood|2014|140